Loading...

Home
ETF
LXRX

LXRX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

LXRX News

Lexicon Pharmaceuticals Closes 32 Million Share Public Offering

Feb 06 2026Newsfilter

Lexicon Pharmaceuticals Prices Public Offering at $1.30 per Share

Jan 30 2026seekingalpha

Lexicon Pharmaceuticals Prices Public Offering at $1.30 per Share

Jan 30 2026Newsfilter

Lexicon Pharmaceuticals Launches Underwritten Public Offering

Jan 29 2026seekingalpha

Lexicon Pharmaceuticals Launches Underwritten Public Offering

Jan 29 2026Newsfilter

Lexicon Pharmaceuticals (LXRX) Advances Pilavapadin to Phase 3 Following Positive FDA Meeting

Jan 21 2026seekingalpha

Lexicon Pharmaceuticals (LXRX) Advances Pilavapadin to Phase 3 After FDA Approval

Jan 21 2026NASDAQ.COM

Progress Software Corp Reports Q4 EPS Beat, Shares Surge 20.5%

Jan 21 2026Benzinga

Lexicon Pharmaceuticals Completes FDA End-of-Phase 2 Meeting, Advancing DPNP Drug Development

Jan 21 2026Globenewswire

Lexicon Pharmaceuticals' SONATA-HCM Study on Track for 2026 Enrollment Completion

Jan 12 2026seekingalpha

Lexicon Pharmaceuticals Triggers $10 Million Milestone Payment with Novo Nordisk for LX9851

Jan 12 2026Globenewswire

Lexicon Pharmaceuticals Releases White Paper Advocating Non-Opioid Pain Treatments

Jan 09 2026Globenewswire

Tilray Brands, SuperX AI Technology, and Other Major Stocks Decline in Friday's Pre-Market Trading

Nov 28 2025Benzinga

Lexicon Pharmaceuticals to Participate in Two Major Healthcare Conferences

Nov 25 2025Newsfilter

Xpeng, Dell, and Other Major Stocks Decline in Pre-Market Trading on Monday

Nov 17 2025Benzinga

Clinical Evidence Showcasing the Effectiveness of Sotagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF) in Non-Diabetic Patients Unveiled at the 2025 American Heart Association (AHA) Annual Scientific Sessions

Nov 08 2025Newsfilter